An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations
Science Translational Medicine · 13.03.2024 · 16 (738)
DOI: 10.1126/scitranslmed.adi0979 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 13.03.2024. Verfasst von Michael Westberg und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurobiology, Stanford University, Stanford, CA 94305, USA. Hauptthemen laut MEDLINE: COVID-19, Coronavirus 3C Proteases. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 147 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
Inhibitors of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (M pro ) such as nirmatrelvir (NTV) and ensitrelvir (ETV) have proven effective in reducing the severity of COVID-19, but the presence of resistance-conferring mutations in sequenced viral genomes raises concerns about future drug resistance. Second-generation oral drugs that retain function against these mutants are thus urgently needed. We hypothesized that the covalent hepatitis C virus protease inhibitor boceprevir (BPV) could serve as the basis for orally bioavailable drugs that inhibit SARS-CoV-2 M pro more efficiently than existing drugs. Performing structure-guided modifications of BPV, we developed a picomolar-affinity inhibitor, ML2006a4, with antiviral activity, oral pharmacokinetics, and therapeutic efficacy similar or superior to those of NTV. A crucial feature of ML2006a4 is a derivatization of the ketoamide reactive group that improves cell permeability and oral bioavailability. Last, ML2006a4 was found to be less sensitive to several mutations that cause resistance to NTV or ETV and occur in the natural SARS-CoV-2 population. Thus, anticipatory design can preemptively address potential resistance mechanisms to expand future treatment options against coronavirus variants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurobiology, Stanford University, Stanford, CA 94305, USA.
- Department of Chemistry, Aarhus University, 8000 Aarhus C, Denmark.
- Interdisciplinary Nanoscience Center (iNANO), Aarhus University, 8000 Aarhus C, Denmark.
- Institute for Translational Brain Research, State Key Laboratory of Medical Neurobiology, MOE Frontiers Center for Brain Science, Fudan University, Shanghai 200032, China.
- Department of Bioengineering, Stanford University, Stanford, CA 94305, USA.
- Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.
ORCID-Profile: Michael Westberg, Yichi Su, Xinzhi Zou, Pinghan Huang, Arjun Rustagi, Jaishree Garhyan, Daniel Fernandez, Yan Wu, Chenzhou Hao, Marwah Karim, Panatda Saenkham-Huntsinger, Vivian Tat, Aleksandra Drelich, Bi-Hung Peng, Shirit Einav, Chien-Te K Tseng, Catherine Blish, Michael Z Lin
Förderung
- NIGMS NIH HHS
- NIAID NIH HHS
Zitieren
APA
Westberg, M., Su, Y., Zou, X., Huang, P., Rustagi, A., Garhyan, J., Patel, P. B., Fernandez, D., Wu, Y., Hao, C., Lo, C. W., Karim, M., Ning, L., Beck, A., Saenkham-Huntsinger, P., Tat, V., Drelich, A., Peng, B. H., Einav, S., …, & Lin, M. Z. (2024). An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations. Science Translational Medicine, 16(738). https://doi.org/10.1126/scitranslmed.adi0979
Vancouver
Westberg M, Su Y, Zou X, Huang P, Rustagi A, Garhyan J, et al. An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations. Science Translational Medicine. 2024;16(738). doi:10.1126/scitranslmed.adi0979
BibTeX
@article{Westberg2024,
author = {Westberg, Michael and Su, Yichi and Zou, Xinzhi and Huang, Pinghan and Rustagi, Arjun and Garhyan, Jaishree and Patel, Puja Bhavesh and Fernandez, Daniel and Wu, Yan and Hao, Chenzhou and Lo, Chieh-Wen and Karim, Marwah and Ning, Lin and Beck, Aimee and Saenkham-Huntsinger, Panatda and Tat, Vivian and Drelich, Aleksandra and Peng, Bi-Hung and Einav, Shirit and Tseng, Chien-Te K and Blish, Catherine and Lin, Michael Z},
title = {An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations},
journal = {Science Translational Medicine},
year = {2024},
volume = {16},
number = {738},
doi = {10.1126/scitranslmed.adi0979}
}
EUVIMED